PURPOSE: To evaluate the effectiveness and tolerability profile of tapentadol prolonged release (PR) in a cohort of head and neck cancer (HNC) patients affected by background pain due to painful mucositis during intensity modulated radiation therapy with or without cisplatin with definitive and adjuvant intent. MATERIALS AND METHODS: Tapentadol PR was administered at the moment of pain onset in opioid-naive patients at the dosage of 50 mg BID. The dosage was increased 50 mg twice a day until the optimal dose of no more than 500 mg/day of tapentadol PR. Primary endpoint of the analysis was the evaluation of improved assessment using the numerical rating scale (NRS). Secondary endpoints were as follows: (1) assessment of the treatment received using the patients' global impression of change (PGIC) scale; (2) weight increase/stability; (3) sleep quality; and (4) tolerability. The period of observation was 90 days from the start of antineoplastic treatment. RESULTS: Between September 2014 and May 2015, 30 HNC patients were observed. The average age was 64.9 years (range, 36-80). Twenty-two days after the start of antineoplastic treatment, tapentadol PR was administered to 25 % of patients. This percentage was increased to 50 % after 39 days and to 75 % after 43 days. Considering the efficacy of tapentadol PR on daily pain, there was a reduction of 30 % (95 % C.I. 69.3 ÷ 96.2 %) in the pain score in 26 patients (86.7 %), and a reduction of 50 % (95 % C.I. 57.7 ÷ 90.1 %) in 23 patients (76.7 %). CONCLUSION: The use of tapentadol PR is feasible and well tolerated in HNC patients affected by background pain due to painful mucositis during intensity modulated radiotherapy with or without cisplatin. Further studies are needed to enhance current findings.
PURPOSE: To evaluate the effectiveness and tolerability profile of tapentadol prolonged release (PR) in a cohort of head and neck cancer (HNC) patients affected by background pain due to painful mucositis during intensity modulated radiation therapy with or without cisplatin with definitive and adjuvant intent. MATERIALS AND METHODS:Tapentadol PR was administered at the moment of pain onset in opioid-naive patients at the dosage of 50 mg BID. The dosage was increased 50 mg twice a day until the optimal dose of no more than 500 mg/day of tapentadol PR. Primary endpoint of the analysis was the evaluation of improved assessment using the numerical rating scale (NRS). Secondary endpoints were as follows: (1) assessment of the treatment received using the patients' global impression of change (PGIC) scale; (2) weight increase/stability; (3) sleep quality; and (4) tolerability. The period of observation was 90 days from the start of antineoplastic treatment. RESULTS: Between September 2014 and May 2015, 30 HNC patients were observed. The average age was 64.9 years (range, 36-80). Twenty-two days after the start of antineoplastic treatment, tapentadol PR was administered to 25 % of patients. This percentage was increased to 50 % after 39 days and to 75 % after 43 days. Considering the efficacy of tapentadol PR on daily pain, there was a reduction of 30 % (95 % C.I. 69.3 ÷ 96.2 %) in the pain score in 26 patients (86.7 %), and a reduction of 50 % (95 % C.I. 57.7 ÷ 90.1 %) in 23 patients (76.7 %). CONCLUSION: The use of tapentadol PR is feasible and well tolerated in HNC patients affected by background pain due to painful mucositis during intensity modulated radiotherapy with or without cisplatin. Further studies are needed to enhance current findings.
Entities:
Keywords:
Head neck cancer; Mucositis; Pain; Radiotherapy; Tapentadol
Authors: W Schröder; T M Tzschentke; R Terlinden; J De Vry; U Jahnel; T Christoph; R J Tallarida Journal: J Pharmacol Exp Ther Date: 2011-01-24 Impact factor: 4.030
Authors: Thomas M Tzschentke; Ulrich Jahnel; Babette Kogel; Thomas Christoph; Werner Englberger; Jean De Vry; Klaus Schiene; Akiko Okamoto; David Upmalis; Horst Weber; Claudia Lange; Jens-Ulrich Stegmann; Regina Kleinert Journal: Drugs Today (Barc) Date: 2009-07 Impact factor: 2.245
Authors: Hans G Kress; E Dietlind Koch; Hristiyan Kosturski; Achim Steup; Keith Karcher; Bernd Lange; Can Dogan; Mila S Etropolski; Marëille Eerdekens Journal: Pain Physician Date: 2014 Jul-Aug Impact factor: 4.965
Authors: Andy Trotti; Lisa A Bellm; Joel B Epstein; Diana Frame; Henry J Fuchs; Clement K Gwede; Eugene Komaroff; Luba Nalysnyk; Marya D Zilberberg Journal: Radiother Oncol Date: 2003-03 Impact factor: 6.280